Tumor Homing Ability Enhanced Synthetic TIL Development Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Introduction

Tumor-infiltrating lymphocytes (TILs) represent a promising frontier in cancer immunotherapy. Their potential to recognize and attack tumor cells offers a powerful tool in the fight against metastatic melanoma and other solid tumors. However, a significant challenge remains: enhancing their homing ability to the tumor site. At Creative Biolabs, we have pioneered the development of synthetic TILs with enhanced tumor-targeting capabilities, leveraging advanced genetic engineering techniques to overcome obstacles that have long limited the efficacy of TIL-based therapies.

Tumor Homing Ability Enhanced Synthetic TIL Development Service

Creative Biolabs offers a cutting-edge service for the development of synthetic TILs, specifically designed to improve their homing ability to tumor sites. By engineering TILs to express chemokine receptors such as CXCR2, we facilitate their migration towards tumors secreting chemokines like CXCL1 and CXCL8, which are prevalent in the tumor microenvironment. This targeted approach not only enhances the effectiveness of the therapy but also minimizes potential off-target effects.

Service Content

Our synthetic TIL development service encompasses several key components:

Chemokine Receptor Engineering

We utilize advanced genetic engineering techniques to introduce and optimize chemokine receptors on TILs, enhancing their ability to hone in on tumor sites effectively.

Large-Scale Expansion

Utilizing state-of-the-art facilities, we ensure rapid expansion and activation of genetically modified TILs under stringent standards, producing robust, viable, and ready-to-use cells.

Customization and Personalization

Each TIL product is customized to recognize a diverse range of tumor-specific antigens, including neoantigens unique to the individual cancer profile.

Related Workflow

Our workflow is meticulously designed to maximize efficiency and efficacy:

Patient-Derived Tumor Sample Collection

Initial steps involve isolating TILs from tumor samples obtained through biopsy.

Genetic Modification

Using a retroviral transduction method, we introduce the gene of interest, such as CXCR2, to augment the homing capabilities of TILs.

Rapid Expansion Protocol (REP) Optimization

Modified TILs undergo REP, a process that enables massive cell growth, maintaining both quantity and functional integrity.

Quality Control and Safety Checks

Each batch of TILs is subjected to rigorous testing to ensure the absence of replication-competent viruses and to verify high transduction efficiency.

Frequently Asked Questions

Q1: How are TILs genetically modified at Creative Biolabs?

A1: We utilize lentiviral and retroviral vectors to introduce genes that code for chemokine receptors, thus equipping TILs with enhanced tumor-targeting abilities.

Q2: How do chemokine modifications improve TIL performance?

A2: Chemokine receptor modifications enhance TIL homing to tumor tissues, augmenting the efficacy of immune-mediated tumor eradication.

Benefits of Our Services

Choosing Creative Biolabs provides unparalleled advantages in the realm of synthetic TIL development:

Fig.1 Our service features. (Creative Biolabs Original)

Creative Biolabs is at the forefront of TIL development, offering a unique combination of scientific expertise and practical solutions to enhance the potency of cancer immunotherapies.